Amgen’s innovative osteoporosis drug is something we can all get behind
Sander Flaum is principal of Flaum Navigators.
Most recent articles by Sander Flaum
Pharma can’t win with critics, even when it makes breakthroughs
Even when pharma produces breakthroughs, critics still find something or other to nitpick.
Continued research depends on fair prices for treatments
Sander Flaum explains why continued research depends on fair prices for treatments.
Why health insurers want to cast pharma as a villain
Sander Flaum takes a look at why health insurers want to cast pharma as the villain.
Focus on drugs’ cost may prevent their discovery
Breakthrough drugs will eventually be more affordable, but a misplaced focus on their cost may prevent them from being discovered at all.
Pharma must consider new approach to opioid crisis
As more and more people die from opioid overdoses, it’s time for pharma to own up to its collective responsibility and come up with a solution.
Should big pharma begin thinking a little smaller?
Big pharma should extend its vision beyond the blockbusters to make room for orphan drugs.
Harness the Power of Paranoia to Disrupt Your Business
In short, CEOs can’t be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.
How About a Moon Shot for Orphan Diseases?
You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.
Back Talk: Hail to the . . . CEO?
Back Talk.pdf Joel Peterson, a favorite Wall Street Journal columnist, recently examined the benefits a CEO might offer as president of the US. I suspect his thesis may have been facetious, but he raised a few intriguing points. The energy and drive of a successful business executive would seem ideal for the Oval Office. Who…
